


This listing of claims will replace all prior versions, and listings, of claims in the application:


**LISTING OF CLAIMS:**

1. (Currently Amended) A pharmaceutical composition comprising:
- (a) ~~an anticholinergic selected from glycopyrronium bromide or an ester of a bi- or tricyclic amino alcohol of formula (I)~~



wherein:

~~Q is one of the groups  $\text{CH}_2\text{CH}_2$ ,  $\text{CH}=\text{CH}$ , or~~




~~R is methyl, ethyl, or propyl optionally substituted by fluorine or hydroxy,~~

~~R' is methyl, ethyl, or propyl, and~~

~~an equivalent of an anion X counters the positive charge of the N atom; and~~

~~Z is one of the groups~~



wherein:

~~Y is a single bond or an O atom;~~

~~R<sup>1</sup> is hydrogen, hydroxy, methoxy, ethoxy, propoxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, or hydroxypropyl;~~

~~R<sup>2</sup> is a thienyl, phenyl, or cyclohexyl group, wherein these groups are optionally substituted by methyl, and thienyl and phenyl are optionally substituted by fluorine or chlorine, and~~

~~R<sup>3</sup> is hydrogen, or a thienyl or phenyl group which is optionally substituted by fluorine, chlorine, or methyl; and~~

- (b) a betamimetic selected from the group consisting of: formoterol; salmeterol; 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3*H*)-benzothiazolone; 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*N,N*-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*n*-butyloxyphenyl)-2-methyl-2-propylamino]ethanol; and 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}ethanol, and a pharmacologically compatible acid addition salt thereof.

**2. – 4. (Canceled)**

- 5. (Original)** The pharmaceutical composition according to claim 1, wherein the betamimetic is formoterol or salmeterol, or a pharmacologically compatible acid addition salt thereof

**6. (Currently Amended)** The pharmaceutical composition according to claim 1, wherein ~~the anticholinergic is tiotropium bromide and~~ the betamimetic is formoterol, or a pharmacologically compatible acid addition salt thereof.

**7. (Currently Amended)** The pharmaceutical composition according to claim 1, wherein ~~the anticholinergic is tiotropium bromide and~~ the betamimetic is salmeterol, or a pharmacologically compatible acid addition salt thereof.

**8. (Canceled)**

**9. (Currently Amended)** The pharmaceutical composition according to one of claims 1 ~~to 8~~ or 5 to 7, wherein the pharmaceutical composition is an inhaled pharmaceutical composition.

**10. (Currently Amended)** A process for the production of a pharmaceutical composition according to one of claims 1, ~~to 8~~ 5 to 7 or 9, comprising:

- (a) mixing the ~~anticholinergic~~ glycopyrronium bromide and the betamimetic; and optionally
- (b) adding an adjuvant and/or carrier materials.

**11. – 14. (Cancelled)**